<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563938</url>
  </required_header>
  <id_info>
    <org_study_id>AK001-001</org_study_id>
    <nct_id>NCT02563938</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 in Subjects With Atopic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allakos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allakos, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human study will evaluate the safety and tolerability of single doses of AK001
      across a range of potentially active doses. Early signals of pharmacodynamic activity will
      also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AK001 is a monoclonal antibody which may be useful in the treatment of patients with severe
      allergic diseases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability of AK001 measured by number of subjects with adverse events and dose limiting toxicities (DLTs) respectively</measure>
    <time_frame>Within 86 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immediate hypersensitivity skin testing</measure>
    <time_frame>Within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood counts for eosinophils and basophils</measure>
    <time_frame>Within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum eosinophilic cationic protein (ECP) and tryptase levels</measure>
    <time_frame>Within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour urine measurement of histamine, N-methylhistamine, and 11-beta-prostaglandin F2</measure>
    <time_frame>Within 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Atopy</condition>
  <arm_group>
    <arm_group_label>AK001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to six single ascending doses of AK001.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution will be administered as a single infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK001</intervention_name>
    <description>Given parenterally.</description>
    <arm_group_label>AK001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Saline Solution</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18-30

          -  Determined to be in good health

          -  Clinical laboratory values within limits of normal values

          -  Normal 12-lead ECG

          -  Stool sample negative for parasites

          -  Non-smoker

          -  Consumed an average of no more than 2 drinks per day within 6 months

          -  Subjects of reproductive age must use a highly effective method of contraception

          -  Positive skin test in certain cohorts

          -  Elevated total eosinophil counts in certain cohorts

        Exclusion Criteria:

          -  Clinically significant medical history conditions or laboratory values

          -  Receipt of investigational drug, biologic or medical device within 30 days prior to
             Screening

          -  New drug therapy within 1 week of study drug administration

          -  Antihistamine use within 2 weeks prior to Screening

          -  Consumption of alcohol within 48 hours of study drug administration

          -  Positive urine drug test or cotinine test at Screening or Day -1

          -  History, within the last 2 years, of alcohol abuse, illicit drug use, or significant
             mental illness

          -  Demonstration of veins unsuitable for repeated venipuncture or IV infusion

          -  Recent treatment with alternative therapies which may confound clinical or laboratory
             assessments

          -  Donation or loss of more than 500 mL of blood within 56 days prior to study drug
             administration

          -  History of malignancy within last 5 years

          -  History of severe allergic or anaphylactic reactions

          -  Females who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allakos, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

